SCHEMBL19965700

SCHEMBL19965700

CS(C)(S)c1ccc(Cl)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.48
CYP3A4 P08684 1/20 0.48
MAPK1 P28482 1/20 0.48
CA1 P00915 4/20 0.44
CA2 P00918 4/20 0.44
CA12 O43570 3/20 0.44
CA3 P07451 3/20 0.44
CA4 P22748 3/20 0.44
CA6 P23280 3/20 0.44
CA5A P35218 3/20 0.44
CA7 P43166 3/20 0.44
CA9 Q16790 3/20 0.44
CA13 Q8N1Q1 3/20 0.44
CA14 Q9ULX7 3/20 0.44
CA5B Q9Y2D0 3/20 0.44
LMNA P02545 1/20 0.44
CYP2A6 P11509 1/20 0.44
PTGS2 P35354 4/20 0.42
IDO1 P14902 1/20 0.41
KDM4E B2RXH2 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19259027 0.77 ALDH1A1 (0.52) ALDH1A1CYP3A4MAPK1CA1CA2
SCHEMBL21533535 0.72 PTGS2 (0.42) ALDH1A1CA1CA2PTGS2MMP1
SCHEMBL265232 0.72 PTGS2 (0.69) ALDH1A1CYP3A4MAPK1CA1CA2
SCHEMBL7536145 0.72 ALDH1A1 (0.62) ALDH1A1CYP3A4MAPK1CA1CA2
SCHEMBL20374370 0.70 PGR (0.43) ALDH1A1LMNAMEN1KMT2AMMP2
SCHEMBL9353231 0.70 ALDH1A1 (0.59) ALDH1A1CYP3A4MAPK1CA1CA2
SCHEMBL10953683 0.70 ALDH1A1 (0.59) ALDH1A1CYP3A4MAPK1CA1CA2
SCHEMBL24062386 0.69 ALDH1A1 (0.58) ALDH1A1CYP3A4MAPK1CA1CA2
SCHEMBL21536600 0.69 PKM (0.56) MAPK1CA1CA2CA12CA7
SCHEMBL486726 0.69 ALDH1A1 (0.56) ALDH1A1CYP3A4MAPK1CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210188786-A1 SUBSTITUTED 1,2,4-TRIAZOLES AND METHODS OF USE STINGINN LLC (US) 2021-06-24 US disclosed
US-10399933-B2 Inhibitors of indoleamine-2,3-dioxygenase for the treatment of cancer BRISTOL-MYERS SQUIBB COMPANY (US) 2019-09-03 US disclosed
US-20180072660-A1 INHIBITORS OF INDOLEAMINE-2,3-DIOXYGENASE FOR THE TREATMENT OF CANCER BRISTOL MYERS SQUIBB CO (US) 2018-03-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210188786-A1 SUBSTITUTED 1,2,4-TRIAZOLES AND METHODS OF USE STING1, IRF3, CGAS ALDH1A1 3318/4885CYP3A4 665/4885MAPK1 3649/4885
US-20180072660-A1 INHIBITORS OF INDOLEAMINE-2,3-DIOXYGENASE FOR THE TREATMENT OF CANCER IDO1, IDO2, INMT ALDH1A1 263/4885CYP3A4 1057/4885MAPK1 1658/4885
US-10399933-B2 Inhibitors of indoleamine-2,3-dioxygenase for the treatment of cancer IDO1, IDO2, INMT ALDH1A1 263/4885CYP3A4 1057/4885MAPK1 1658/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.